$ABMD (ABIOMED, Inc.)

$ABMD {{ '2016-02-08T17:10:04+0000' | timeago}} • Announcement

Medical devices company $ABMD said it has appointed Jeannine Rivet and Christopher Van Gorder to its BoD, bringing the number of active directors to nine. Ms. Rivet is currently EVP of UnitedHealth Group and Mr. Van Gorder has been President and CEO of Scripps Health since 2000.

$GILD {{ '2017-07-27T19:17:21+0000' | timeago}} • Webcast

$GILD stated that for Genvoya, it is starting to see performance trends similar to that of the US in other countries like Germany. The company is seeing good uptake in Spain and Italy. France has also done extraordinarily well in just four months to become the leading naïve and switch product.

$CELG {{ '2017-07-27T19:16:33+0000' | timeago}} • Announcement

For FY17, $CELG cut down its GAAP EPS outlook to $5.36-5.62 from its prior estimate of $5.95-6.29. However, Celgene lifted its non-GAAP EPS outlook to $7.25-7.35 from its previous estimate of $7.15-7.30. The company didn't alter its previous revenue outlook of $13.0-13.4Bil.

$GILD {{ '2017-07-27T19:04:57+0000' | timeago}} • Webcast

For HCV, $GILD’s total revenues in the US were $1.9Bil in 2Q17, down 17% YoY and up 13% sequentially. The QoQ increase was primarily due to a change in inventory and the timing of patient starts. In Europe, total HCV revenue was $591MM, down 24% YoY and up 21% from 1Q17.

$GILD {{ '2017-07-27T19:00:11+0000' | timeago}} • Webcast

$GILD is seeing strong uptake of its TAF-based regimens in the US and Europe. In the US, total HIV and HBV revenues were $2.6Bil for 2Q17, up 19% YoY and up 10% sequentially. In Europe, total HIV and HBV revenues were $732MM, down 3% YoY and up 5% sequentially. The YoY decrease was driven by negative foreign exchange.

$CELG {{ '2017-07-27T18:53:16+0000' | timeago}} • Announcement

Biotech heavyweight $CELG reported strong profit in 2Q17, helped by higher product sales. Net income of $1.06Bil and diluted EPS of $1.31, surged 77% and 75%, respectively. Total revenue rose 19% to $3.3Bil, while  net product sales alos increased 19% for the recent quarter. Celgene's earnings grew 26% to $1.82 per share on an adjusted basis.

$GILD {{ '2017-07-27T18:32:52+0000' | timeago}} • Announcement

$GILD declared a cash dividend of $0.52 per share of common stock for 3Q17, payable on September 28, 2017, to stockholders of record on September 15, 2017.

$CELG {{ '2017-07-27T14:01:16+0000' | timeago}} • Infographic

$CELG Celgene Earnings AlphaGraphic: Q2 2017 highlights

$BMY {{ '2017-07-27T12:44:31+0000' | timeago}} • Infographic

$BMY Bristol-Myers Squibb Co Earnings AlphaGraphics: Q2 2017 highlights

$BMY {{ '2017-07-27T11:32:39+0000' | timeago}} • Announcement

$BMY updated its FY17 GAAP EPS guidance range to $2.66-2.76 and raised the lower end of its non-GAAP EPS guidance range to $2.90-3.00, as the pharma giant posted 2Q17 results.

$BMY {{ '2017-07-27T11:30:29+0000' | timeago}} • Announcement

As $BMY posted its 2Q17 results, it also announced that the European Commission (EC) approved its drug ORENCIA alone or in combination with methotrexate for the treatment of active Psoriatic Arthritis in certain adult patients.

$BMY {{ '2017-07-27T11:28:03+0000' | timeago}} • Announcement

A 31% surge in R&D expenses of $1.7Bil in 2Q17 saw $BMY's net attributable earnings slumping 24% to $916MM, even as revenue rose 6% to $5.1Bil. Diluted EPS slipped 19% to $0.56, while non-GAAP diluted EPS rose 7% to $0.74.

$GILD {{ '2017-07-26T21:10:46+0000' | timeago}} • Infographic

$GILD Gilead Sciences Earnings AlphaGraphic: Q2 2017 Highlights

$VRTX {{ '2017-07-26T20:38:11+0000' | timeago}} • Announcement

$VRTX also reviewed its recent progress toward treating all people with cystic fibrosis, including the completion of an asset purchase agreement with Concert Pharmaceuticals for worldwide development and commercialization rights to CTP-656 and other assets related to the treatment of cystic fibrosis.

$GILD {{ '2017-07-26T20:37:51+0000' | timeago}} • Announcement

$GILD revised its FY17 guidance. The company now expects net product sales to be $24-25.5Bil in FY17. Non-HCV product sales are expected to be $15.5-16Bil while HCV product sales are expected to be $8.5-9.5Bil. Adjusted product gross margin is expected to be 86-88% in FY17.

$VRTX {{ '2017-07-26T20:36:21+0000' | timeago}} • Announcement

$VRTX lifted 2017 non-GAAP combined research & development and selling, general & administrative expenses outlook to $1.33-1.36Bil from $1.25-1.30Bil, and GAAP combined R&D and SG&A expenses estimate to $1.79-1.92 from $1.55-1.70. The updated forecast reflects the progression of the company's cystic fibrosis portfolio.

$GILD {{ '2017-07-26T20:33:53+0000' | timeago}} • Announcement

$GILD's total product sales for 2Q17 were $7Bil compared to $7.7Bil for 2Q16. Product sales were $5Bil in the US, $1.4Bil in Europe and $665MM in other locations during 2Q17. Antiviral product sales were $6.4Bil and Other product sales were $607MM for 2Q17.

$VRTX {{ '2017-07-26T20:33:48+0000' | timeago}} • Announcement

$VRTX expects 2017 total cystic fibrosis product revenue of $1.84-2.07Bil, comprised of Orkambi and Kalydeco product revenues. $VRTX still expects 2017 product revenue for Orkambi of $1.1-1.3Bil and for Kalydeco of $740-770MM.

$VRTX {{ '2017-07-26T20:30:18+0000' | timeago}} • Announcement

$VRTX's net product revenues from cystic fibrosis therapy Orkambi for 2Q17 increased to $324.4MM from $245.5MM last year. This was primarily driven by the continued uptake in the medicine globally and additional uptake in people with cystic fibrosis ages 6 to 11 in the U.S., where approval was received in September 2016.

$GILD {{ '2017-07-26T20:29:32+0000' | timeago}} • Announcement

$GILD posted a slight decrease in 2Q17 results. Net income was $3.1Bil or $2.33 per share compared to $3.5Bil or $2.58 per share in 2Q16. Adjusted net income was $3.4Bil or $2.56 per share in 2Q17. Total revenues were $7.1Bil compared to $7.8Bil in the prior-year period.

$VRTX {{ '2017-07-26T20:26:38+0000' | timeago}} • Announcement

$VRTX reported net income for 2Q17 of $31.17MM or $0.07 per share compared to a loss of $64.53MM or $0.26 per share last year. This swing in results was driven by higher revenue as well as a decline in interest expenses. Revenue grew to $544.14MM from $431.61MM. Non-GAAP EPS increased to $0.39 from $0.24.

Recent Transcripts

BMY (Bristol-Myers Squibb Company)
Thursday, July 27 2017 - 2:30pm
CELG (Celgene Corporation)
Thursday, July 27 2017 - 1:00pm
BSX (Boston Scientific Corporation)
Thursday, July 27 2017 - 12:00pm
VRTX (Vertex Pharmaceuticals Incorporated)
Wednesday, July 26 2017 - 9:15pm
MMSI (Merit Medical Systems, Inc.)
Wednesday, July 26 2017 - 9:00pm
GILD (Gilead Sciences Inc.)
Wednesday, July 26 2017 - 8:30pm
MMM (3M Company)
Tuesday, July 25 2017 - 1:00pm
ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm
ATRS (Antares Pharma Inc.)
Tuesday, May 9 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, May 9 2017 - 12:00pm
ABMD (ABIOMED, Inc.)
Thursday, May 4 2017 - 12:00pm
TFX (Teleflex Incorporated)
Thursday, May 4 2017 - 12:00pm
AMRN (Amarin Corporation plc)
Wednesday, May 3 2017 - 12:00pm
KTWO (K2M Group Holdings, Inc.)
Tuesday, May 2 2017 - 9:00pm
GILD (Gilead Sciences Inc.)
Tuesday, May 2 2017 - 8:30pm
MMSI (Merit Medical Systems, Inc.)
Thursday, April 27 2017 - 9:00pm
VRTX (Vertex Pharmaceuticals Incorporated)
Thursday, April 27 2017 - 8:30pm
SPNC (The Spectranetics Corporation)
Thursday, April 27 2017 - 8:30pm
RMD (ResMed Inc.)
Thursday, April 27 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, April 27 2017 - 2:30pm

AlphaGraphics you may like